4.7 Review

microRNAs in cancer management

Journal

LANCET ONCOLOGY
Volume 13, Issue 6, Pages E249-E258

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(12)70073-6

Keywords

-

Categories

Funding

  1. Medical Research Council
  2. BBSRC [BB/F019017/1, BB/F011806/1, BB/F019017/2, BB/F011806/2] Funding Source: UKRI
  3. MRC [MC_UP_A600_1024] Funding Source: UKRI
  4. Biotechnology and Biological Sciences Research Council [BB/F019017/2, BB/F019017/1, BB/F011806/1, BB/B500915/1, BB/F011806/2] Funding Source: researchfish
  5. Medical Research Council [MC_UP_A600_1024] Funding Source: researchfish

Ask authors/readers for more resources

Since the identification of microRNAs (miRNAs) in 1993, and the subsequent discovery of their highly conserved nature in 2000, the amount of research into their function-particularly how they contribute to malignancy-has greatly increased. This class of small RNA molecules control gene expression and provide a previously unknown control mechanism for protein synthesis. As such, it is unsurprising that miRNAs are now known to play an essential part in malignancy, functioning as tumour suppressors and oncogenes. This Review summarises the present understanding of how miRNAs operate at the molecular level; how their dysregulation is a crucial part of tumour formation, maintenance, and metastasis; how they can be used as biomarkers for disease type and grade; and how miRNA-based treatments could be used for diverse types of malignancies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available